×

Warning

JUser: :_load: Unable to load user with ID: 151

Tuesday, 24 September 2013 07:46

Use of enoxaparin in end-stage renal disease

By 
Rate this item
(1 Vote)

Enoxaparin has become the treatment of choice for various thromboembolic diseases. In most patients with end-stage renal disease (ESRD), prophylactic dosage of enoxaparin does not appear to be associated with an increased bleeding risk and can be used without the need for monitoring and adjustment of regimens. Empirical dose adjustment and biological monitoring seem to be necessary along with therapeutic doses. Anti-factor Xa poorly predicts the degree of anticoagulation in ESRD patients given enoxaparin.

 

http://www.nature.com/ki/journal/v84/n3/full/ki2013163a.html
Silvia Lai and Bettina Coppola
Kidney Int 84: 433-436; doi:10.1038/ki.2013.163

Additional Info

  • Language: English
  • Contains Audio: No
  • Content Type: Articles
  • Source: KI
  • Year: 2013
  • Members Only: No
Read 7184 times Last modified on Monday, 16 January 2017 15:54

Global Operations Center

Avenue des Arts 1-2
1210 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact

               

Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact